Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

ABSTRACT: An increasing focus on personalized medicine is driving a renewed effort to understand the impact of ethnic and genetic background on treatment outcomes. Since responses to psychopharmacological treatments continue to be sub-optimal, there is a pressing need to identify markers of tolerability and efficacy. Pharmacogenomic studies aim to find such markers within the human genome, and have made some progress in recent years. Progress has been slower in populations with diverse racial and ethnic backgrounds. Here we review 10 genome-wide association studies (GWAS) that assessed outcomes after antidepressant, antipsychotic, or mood stabilizer treatment. These studies used samples collected by the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), Sequenced Treatment Alternat

SUBMITTER: Murphy E 

PROVIDER: S-EPMC6011657 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature